Mayo Clinic-led Team Identifies Master Switch for Cancer-Causing HER2 Protein

ROCHESTER, Minn. — Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. A team of researchers [...]
Source: Mayo Clinic Rochester News - Category: Hospital Management Source Type: news